利拉鲁肽对比安慰剂对2型糖尿病心血管高危患者急性胆囊或胆道疾病事件的影响:LEADER随机试验
LEADER试验事后分析纳入9340例心血管高危的2型糖尿病患者,随机接受利拉鲁肽(≤1.8 mg/日)或安慰剂。利拉鲁肽组急性胆囊或胆道疾病风险高于安慰剂组(HR 1.60,95%CI 1.23-2.09,P<0.001),胆囊切除术也更常见(HR 1.56,95%CI 1.10-2.20,P=0.013)。
要点
- 利拉鲁肽增加急性胆囊或胆道疾病风险(HR 1.60,95%CI 1.23-2.09)。
- 四类胆囊/胆道事件均呈相似趋势。
- 胆囊切除术在利拉鲁肽组更常见(HR 1.56,95%CI 1.10-2.20)。
核心结论
- 利拉鲁肽对比安慰剂增加2型糖尿病心血管高危患者急性胆囊或胆道疾病事件风险,四类事件趋势一致,需进一步研究机制。
研究设计与样本
- LEADER为国际、随机、双盲、对照心血管结局试验,纳入9340例心血管高危的2型糖尿病患者,1:1随机接受利拉鲁肽(≤1.8 mg/日,n=4668)或安慰剂(n=4672),均接受标准治疗,治疗期3.5-5年。
主要发现
- 利拉鲁肽组141/4668例 vs 安慰剂组88/4672例发生急性胆囊或胆道疾病(HR 1.60;95%CI 1.23,2.09;P<0.001)。
- 四类胆囊或胆道相关事件(非复杂性胆囊结石、复杂性胆囊结石、胆囊炎、胆道梗阻)均观察到相似趋势。
- 胆囊切除术在利拉鲁肽组更频繁(HR 1.56;95%CI 1.10,2.20;P=0.013),但在发生胆囊或胆道事件的患者中比例相似(利拉鲁肽57% vs 安慰剂59%)。
临床怎么用
- 对心血管高危的2型糖尿病患者使用利拉鲁肽时,应关注急性胆囊或胆道疾病风险,尤其需警惕胆囊切除术可能。
局限性
- LEADER并非专门设计评估急性胆囊或胆道疾病。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To explore gallbladder- and biliary tract-related events reported for the liraglutide and placebo groups in the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) trial. RESEARCH DESIGN AND METHODS: LEADER was an international, randomized, double-blind, controlled cardiovascular (CV) outcomes trial. Participants with type 2 diabetes at high risk for CV events (n = 9,340) were randomized 1:1 to receive either liraglutide (≤1.8 mg daily; n = 4,668) or placebo (n = 4,672), with both groups also receiving standard care (treatment period: 3.5-5 years). Acute gallstone disease was a medical event of special interest. This post hoc analysis categorized captured events of acute gallbladder or biliary disease into four groups: uncomplicated gallbladder stones, complicated gallbladder stones, cholecystitis, and biliary obstruction. Time to first event by treatment group was analyzed using Cox regression. RESULTS: There was an increased risk of acute gallbladder or biliary disease with liraglutide versus placebo (n = 141 of 4,668 vs. n = 88 of 4,672 patients, respectively; hazard ratio [HR] 1.60; 95% CI 1.23, 2.09; P < 0.001). Similar trends were observed for each of the four categories of gallbladder- or biliary tract-related events. Cholecystectomy was performed more frequently in liraglutide-treated patients (HR 1.56; 95% CI 1.10, 2.20; P = 0.013) but for similar proportions of the patients who experienced gallbladder- or biliary tract-related events (57% with liraglutide vs. 59% with placebo). CONCLUSIONS: Although LEADER was not specifically designed to assess acute gallbladder or biliary disease, the trial showed an increased risk of gallbladder- or biliary tract-related events with liraglutide versus placebo, which appeared to be consistent across four categories of these events. Further studies should investigate the relevant mechanisms.
引用
- Nauck MA, Muus Ghorbani ML, Kreiner E, et al. Effects of Liraglutide Compared With Placebo on Events of Acute Gallbladder or Biliary Disease in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events in the LEADER Randomized Trial. Diabetes Care. 2019. PMID: 31399438. doi:10.2337/dc19-0415
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。